Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - Elsevier
Background Approximately 5% of non-small cell lung cancer (NSCLC) patients develop
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom
die. However, there are no established risk factors for its occurrence. Interstitial lung
abnormalities (ILA) are areas of increased lung density on lung computed tomography (CT)
in individuals with no known ILD. This study retrospectively investigated whether any patient
characteristics, including ILA, were risk factors for ICI-ILD in patients with NSCLC. Methods …
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom
die. However, there are no established risk factors for its occurrence. Interstitial lung
abnormalities (ILA) are areas of increased lung density on lung computed tomography (CT)
in individuals with no known ILD. This study retrospectively investigated whether any patient
characteristics, including ILA, were risk factors for ICI-ILD in patients with NSCLC. Methods …
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers.
K Shimoji, T Masuda, Y Nakanishi, K Yamaguchi… - 2020 - ascopubs.org
e15171 Background: Immune check point inhibitor (ICI) induced interstitial lung disease (ICI-
ILD) is a clinically serious and life-threatening toxicity. Pre-existing ILD has been reported to
be a risk factor for ICI-ILD in patients with non-small cell lung cancer (NSCLC). In addition,
we have previously reported that interstitial lung abnormality (ILA) is also a risk factor for the
ICI-ILD. Therefore, we investigated whether any patient characteristics, including ILA, were
risk factors for ICI-ILD in patients with non-NSCLC cancers. Methods: Head and neck …
ILD) is a clinically serious and life-threatening toxicity. Pre-existing ILD has been reported to
be a risk factor for ICI-ILD in patients with non-small cell lung cancer (NSCLC). In addition,
we have previously reported that interstitial lung abnormality (ILA) is also a risk factor for the
ICI-ILD. Therefore, we investigated whether any patient characteristics, including ILA, were
risk factors for ICI-ILD in patients with non-NSCLC cancers. Methods: Head and neck …